$CRSP
CRISPR Therapeutics AG

2023 Q3 Form 10-Q Financial Statement

#000095017023039075 Filed on August 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $70.00M
YoY Change -100.0% 44203.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $41.70M $63.67M
YoY Change -36.68% 5.77%
% of Gross Profit
Research & Development $90.70M $101.6M
YoY Change -22.23% -17.58%
% of Gross Profit
Depreciation & Amortization $4.900M $4.961M
YoY Change -2.0% -32.04%
% of Gross Profit
Operating Expenses $132.4M $165.2M
YoY Change -27.44% -9.92%
Operating Profit -$132.4M -$95.22M
YoY Change -27.4% -48.04%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $20.67M $18.41M
YoY Change 184.57% 419.36%
Pretax Income -$111.7M -$76.82M
YoY Change -36.19% -57.26%
Income Tax $400.0K $923.0K
% Of Pretax Income
Net Earnings -$112.2M -$77.74M
YoY Change -35.75% -58.17%
Net Earnings / Revenue -111.06%
Basic Earnings Per Share -$1.41 -$0.98
Diluted Earnings Per Share -$1.41 -$0.98
COMMON SHARES
Basic Shares Outstanding 79.41M 78.94M
Diluted Shares Outstanding 79.41M 79.09M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $677.0M $1.768B
YoY Change -12.54% 100.88%
Cash & Equivalents $527.8M $444.8M
Short-Term Investments $149.2M $1.323B
Other Short-Term Assets $20.80M $21.47M
YoY Change -43.29% -48.46%
Inventory
Prepaid Expenses
Receivables $70.00M
Other Receivables $0.00
Total Short-Term Assets $1.761B $1.860B
YoY Change -8.91% -11.75%
LONG-TERM ASSETS
Property, Plant & Equipment $156.1M $318.5M
YoY Change -6.01% 92.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $4.901M
YoY Change -100.0% -41.6%
Other Assets $2.047M $13.97M
YoY Change -44.41% 271.65%
Total Long-Term Assets $326.2M $337.4M
YoY Change -22.44% -5.29%
TOTAL ASSETS
Total Short-Term Assets $1.761B $1.860B
Total Long-Term Assets $326.2M $337.4M
Total Assets $2.087B $2.197B
YoY Change -11.33% -10.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.15M $27.59M
YoY Change -18.57% 9.29%
Accrued Expenses $66.41M $104.7M
YoY Change -35.5% 27.3%
Deferred Revenue $3.500M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $111.2M $132.8M
YoY Change -26.27% 10.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.394M $248.1M
YoY Change 1.51% 3973.36%
Total Long-Term Liabilities $5.394M $248.1M
YoY Change 1.51% 3973.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $111.2M $132.8M
Total Long-Term Liabilities $5.394M $248.1M
Total Liabilities $359.0M $381.0M
YoY Change -10.11% 2.27%
SHAREHOLDERS EQUITY
Retained Earnings -$1.089B -$976.9M
YoY Change 48.07% 74.15%
Common Stock $2.824B $2.802B
YoY Change 4.13% 4.85%
Preferred Stock
YoY Change
Treasury Stock (at cost) $63.00K $63.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $1.728B $1.816B
YoY Change
Total Liabilities & Shareholders Equity $2.087B $2.197B
YoY Change -11.33% -10.81%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$112.2M -$77.74M
YoY Change -35.75% -58.17%
Depreciation, Depletion And Amortization $4.900M $4.961M
YoY Change -2.0% -32.04%
Cash From Operating Activities -$39.90M -$133.2M
YoY Change -62.08% -6.14%
INVESTING ACTIVITIES
Capital Expenditures $3.100M $5.055M
YoY Change -151.52% -152.49%
Acquisitions
YoY Change
Other Investing Activities $124.4M $222.0M
YoY Change 33.08% -577.97%
Cash From Investing Activities $121.3M $216.9M
YoY Change 38.69% -486.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.500M 16.77M
YoY Change -90.07% 61.93%
NET CHANGE
Cash From Operating Activities -39.90M -133.2M
Cash From Investing Activities 121.3M 216.9M
Cash From Financing Activities 1.500M 16.77M
Net Change In Cash 82.90M 100.4M
YoY Change -3237.77% -153.52%
FREE CASH FLOW
Cash From Operating Activities -$39.90M -$133.2M
Capital Expenditures $3.100M $5.055M
Free Cash Flow -$43.00M -$138.3M
YoY Change -56.65% 4.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001674416
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37923
dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
dei Entity Address Country
EntityAddressCountry
CH
dei City Area Code
CityAreaCode
41 (0)41
dei Local Phone Number
LocalPhoneNumber
561 32 77
dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
dei Trading Symbol
TradingSymbol
CRSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79411450
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
444796000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
211885000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1323307000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1603433000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
70000000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21469000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
37708000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
1859572000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1853026000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
159172000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163634000
CY2023Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
4901000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
53130000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
71000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11799000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11635000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
159352000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
156921000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2175000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4640000
CY2023Q2 us-gaap Assets
Assets
2197014000
CY2022Q4 us-gaap Assets
Assets
2243057000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
27588000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
27428000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
89838000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
77682000
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
558000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
135000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14833000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15842000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
132837000
crsp Collaboration Expense
CollaborationExpense
64568000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
165223000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
121107000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
230342000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
228179000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5484000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5969000
CY2023Q2 us-gaap Liabilities
Liabilities
380986000
CY2022Q4 us-gaap Liabilities
Liabilities
367578000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79552682
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78692766
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79372366
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78512450
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
2474000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2441000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
180316
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
180316
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2799420000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2734838000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-976895000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-846090000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8908000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15647000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1816028000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1875479000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2197014000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2243057000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70000000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
158000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
170000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101555000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
123223000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
201490000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
241468000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19032000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26273000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41392000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54294000
CY2023Q2 crsp Collaboration Expense
CollaborationExpense
44636000
CY2022Q2 crsp Collaboration Expense
CollaborationExpense
33922000
crsp Collaboration Expense
CollaborationExpense
86828000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
183418000
us-gaap Operating Expenses
OperatingExpenses
329710000
us-gaap Operating Expenses
OperatingExpenses
360330000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-95223000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-183260000
us-gaap Operating Income Loss
OperatingIncomeLoss
-159710000
us-gaap Operating Income Loss
OperatingIncomeLoss
-359232000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18406000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3544000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31148000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3907000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18406000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3544000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31148000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3907000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76817000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-179716000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-128562000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-355325000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
923000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6118000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2243000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9726000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77740000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-185834000
us-gaap Net Income Loss
NetIncomeLoss
-130805000
us-gaap Net Income Loss
NetIncomeLoss
-365051000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
28000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-69000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
60000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-95000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
452000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3380000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6679000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15180000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77260000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-189283000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124066000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-380326000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.72
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79091061
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77513327
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78885168
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77306970
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.72
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79091061
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77513327
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78885168
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77306970
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10010000
CY2022Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
740000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25745000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11826000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-179217000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2244916000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10346000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24852000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3449000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-185834000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2090831000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1875479000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
5000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4683000
CY2023Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
660000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20875000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
6259000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-53065000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1854896000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16623000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21765000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
480000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77740000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1816028000
us-gaap Profit Loss
ProfitLoss
-130805000
us-gaap Profit Loss
ProfitLoss
-365051000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10012000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13308000
us-gaap Share Based Compensation
ShareBasedCompensation
42640000
us-gaap Share Based Compensation
ShareBasedCompensation
50597000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
5620000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-9671000
crsp Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
1500000
crsp Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
70000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-239000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15952000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2032000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13637000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8303000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1011000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-1277000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
5865000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-485000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1148000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-124446000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-277195000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6614000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24980000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
1500000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
452363000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
597136000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
795229000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
451529000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
334752000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170587000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
22169000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21002000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22169000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21002000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-95000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
232535000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-426875000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
224060000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
939944000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
456595000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
513069000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1029000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5016000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
293000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
241000
crsp Leasehold Improvements Paid Directly By Landlord
LeaseholdImprovementsPaidDirectlyByLandlord
0
crsp Leasehold Improvements Paid Directly By Landlord
LeaseholdImprovementsPaidDirectlyByLandlord
19252000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
444796000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
496893000
CY2023Q2 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
0
CY2022Q2 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
4053000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11799000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12123000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
456595000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
513069000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2023Q2 us-gaap Marketable Securities
MarketableSecurities
331400000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
159300000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
113355000
CY2023Q2 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
5000
CY2023Q2 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
0
CY2023Q2 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
113360000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1337137000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
513000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9442000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1328208000
CY2023Q2 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1450492000
CY2023Q2 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
518000
CY2023Q2 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
9442000
CY2023Q2 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1441568000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
52592000
CY2022Q4 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
0
CY2022Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
2000
CY2023Q2 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
836000
CY2022Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
1244000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1161000
CY2022Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
52590000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1672164000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
626000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16227000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1656563000
CY2022Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1724756000
CY2022Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
626000
CY2022Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
16229000
CY2022Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1709153000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
8900000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15600000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
820200000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
628400000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
298500000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
619200000
CY2023Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
4900000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
53100000
CY2023Q2 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
202988000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
197466000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43816000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33832000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
159172000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163634000
CY2023Q2 us-gaap Depreciation
Depreciation
5000000
us-gaap Depreciation
Depreciation
10000000.0
CY2022Q2 us-gaap Depreciation
Depreciation
7300000
us-gaap Depreciation
Depreciation
13300000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12583000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19241000
CY2023Q2 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
20197000
CY2022Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
35010000
CY2023Q2 crsp Accrued Collaboration Costs
AccruedCollaborationCosts
45901000
CY2022Q4 crsp Accrued Collaboration Costs
AccruedCollaborationCosts
11177000
CY2023Q2 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
2055000
CY2022Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
983000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4391000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4927000
CY2023Q2 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
2714000
CY2022Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3936000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1164000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
89838000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
77682000
CY2022 crsp Deferred Finance Costs Share Lending Arrangement Issuance Costs
DeferredFinanceCostsShareLendingArrangementIssuanceCosts
36100000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2023Q2 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
20989313
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21765000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24852000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42640000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50597000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7230233
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
60.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1358782
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
45.58
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
570185
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
38.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
690798
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
86.7
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7328032
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
56.73
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4637268
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
53.23
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7328032
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
56.73
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
101700000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8887196
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8912465
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8887196
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8912465
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2200000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.012
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.017
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9700000
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.034
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.027
ecd Trd Arr Adoption Date
TrdArrAdoptionDate
June 16, 2023
ecd Trd Arr Ind Name
TrdArrIndName
Dr. Rodger Novak
ecd Trd Arr Ind Title
TrdArrIndTitle
President and Chairman
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2023Q2 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
100000

Files In Submission

Name View Source Status
Financial_Report.xlsx Edgar Link pending
0000950170-23-039075-index-headers.html Edgar Link pending
0000950170-23-039075-index.html Edgar Link pending
0000950170-23-039075.txt Edgar Link pending
0000950170-23-039075-xbrl.zip Edgar Link pending
crsp-20230630.htm Edgar Link pending
crsp-20230630.xsd Edgar Link pending
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
crsp-20230630_cal.xml Edgar Link unprocessable
crsp-20230630_def.xml Edgar Link unprocessable
crsp-20230630_lab.xml Edgar Link unprocessable
crsp-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crsp-20230630_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending